Results

1–10 of 624 results for ASC

Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2023
Ellipsoid Zone Integrity Preservation and Characterization of Ellipsoid Zone Integrity Features in the GATHER 1 Phase 2/3 Study
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2023
Intravitreal Avacincaptad Pegol in Geographic Atrophy: Post-Hoc Analysis of Vision Loss From the GATHER Clinical Program
Carl J Danzig, MD
Annual Meeting Talks
2023
Retinal Tissue Preservation With Intravitreal Pegcetacoplan in Patients With Geographic Atrophy
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2023
Effect of Pegcetacoplan on Photoreceptor and Retinal Pigment Epithelium Integrity in Geographic Atrophy in the Phase 3 Trials and GALE Extension Study
Ursula M. Schmidt-Erfurth, MD
Annual Meeting Talks
2023
Long-Term Efficacy of Pegcetacoplan in Patients With Geographic Atrophy
Nathan C. Steinle, MD
Annual Meeting Talks
2023
Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration With Intravitreal ANX007: Results of the ARCHER Study
Jeffrey S. Heier, MD
Annual Meeting Talks
2023
Daily Imaging With Home Optical Coherence Tomography Among Treatment-Naive Neovascular Age-Related Macular Degeneration Participants
Kevin J. Blinder, MD, FASRS
Annual Meeting Talks
2023
Accuracy and Residual Volume of Commonly Used Syringes for Intravitreal Injection and the Impact on Intraocular Pressure
Gustavo Barreto de Melo, MD, PhD, FASRS
Annual Meeting Talks
2023